TriangleM28z1XXPD1DNR CAR (NCT06623396)
M28z1XXPD1DNR CAR trial for Mesothelin-Expressing Tumors (NCT06623396). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When stomach or esophageal cancer spreads across the lining of the abdomen, chemotherapy reaches it poorly, and survival is measured in months.
The idea: put engineered T cells directly into the abdominal cavity, and armor them against the tumor's off switch.
Most of these tumors carry mesothelin on their surface. At Memorial Sloan Kettering, a patient's own T cells receive a receptor for mesothelin, tuned to fire without exhausting, plus a decoy PD-1 receptor: it catches the tumor's shut-down signal but cannot pass it on. The cells are infused into the peritoneal cavity, where the disease is, rather than into a vein.
An early dose-finding study for metastatic esophagogastric adenocarcinoma with peritoneal spread. Geoffrey Ku leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.